Chronic exposure to GLP-1Ra appears to be essentially neutral on both 2D systolic and diastolic function, irrespective of LV EF
Sources Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies Diabetes, Obesity and Metabolism, Neeland et al., 2024 Muscle Mass and Glucagon-Like Peptide-1 Receptor Agonists: Adaptive or Maladaptive Response to Weight Loss
Additional regulations None Oklahoma Who can prescribe semaglutide
As evidence mounts, pharmaceutical stakeholders highlight its significance in chronic weight management
As we all know, typical self-induced restrictive diets are ineffective
What typically happens when you stop: GI side effects (nausea, bloating, constipation) begin to resolve within days to 2 weeks after stopping